Background
Methods
Patients
Clinical sample collection and DNA extraction
Library preparation and sequencing
Data processing
Statistical analysis
Results
Mutation profiling in Chinese mCRC patients
Patient number (percentage of patients) | P value* | |
---|---|---|
Total patient number | 33 | |
Age(years) | 0.50 | |
< 65 | 26(78.8) | |
≥ 65 | 7 (21.2) | |
Gender | 0.47 | |
Male | 24(72.7) | |
Female | 9(27.2) | |
Location of primary tumor | 0.76 | |
Colon | 24(72.7) | |
Rectum | 9(27.2) | |
Number of metastatic sites | 0.15 | |
< 3 | 26(84.8) | |
≥ 3 | 7(15.2) | |
Liver metastases | 0.80 | |
Yes | 19(54.5) | |
No | 14(45.5) | |
ECOG performance status | 0.007** | |
0 or 1 | 24(72.7) | |
2 | 9(27.2) | |
Histological type | 0.30 | |
Adenocarcinoma | 28(84.8) | |
Mucinous | 5(15.2) | |
Previous chemotherapy treatment | 0.70 | |
No | 27 (81.8) | |
Yes | 6 (18.2) |
Identification of SMAD4 and NF1 mutations as biomarkers for poor prognosis upon cetuximab-based therapy
Number of patients (n=) | Median PFS (days) | |
---|---|---|
Total patients | 33 | 211 |
SMAD4
mut
| 8 | 90 |
SMAD4
wt
| 25 | 250 |
NF1
mut
| 4 | 53.5 |
NF1
wt
| 29 | 211 |
SMAD4mut or NF1mut | 10 | 90 |
SMAD4wt and NF1wt | 23 | 250 |
KRAS
mut
| 9 | 99 |
KRAS
wt
| 24 | 230.5 |